title: ERM/ETV5 and RUNX1/AML1 expression in endometrioid adenocarcinomas of endometrium and association with neoplastic progression.
abstract: The majority of endometrioid endometrial carcinomas (EEC) is diagnosed at stage I. Among these, 30% present myometrial invasion (stage IB), which is associated with tumor spread and relapse after primary treatment. Although an increased expression of RUNX1/AML1 and ERM/ETV5 in EEC have been suggested to be associated with early events of myometrial infiltration, there is no data regarding its expression along the evolution of EEC and possible associations with other clinicopathological parameters. Therefore, ERM/ETV5 and RUNX1/AML1 protein and gene expression profiles were assessed in different EEC stages to evaluate their role in endometrial carcinogenesis. RUNX1/AML1 and ERM/ETV5 proteins were analyzed by immunohistochemistry in 219 formalin fixed paraffin embedded endometrioid tumors and in 12 normal atrophic and proliferative endometrium samples. RUNX1/AML1 and ERM/ETV5 genes expression were analyzed by RT-qPCR. RUNX1/AML1 and ERM/ETV5 expression were decreased with increasing EEC stage, with a positive correlation between protein and gene expression for ERM/ETV5, but not for RUNX1/AML1. Both proteins were present in the nucleus of the tumor cells, whereas RUNX1/AML1, but not ERM/ETV5, was expressed in 7 out of 12 normal endometrial samples, with its expression being restricted to the cytoplasm of the positive cells. We concluded that there is a higher expression of ERM/ETV5 in early stages of EEC, whereas there seems to be a RUNX1/AML1 translocation from cytoplasm to nucleus in EEC neoplastic transformation.
authors.affiliation: Programa de Carcinogênese Molecular; Centro de Pesquisa (CPQ); Instituto Nacional de Câncer (INCA); Rio de Janeiro, Brazil.
authors.forename: Vanessa Paiva Leite
authors.initials: VP
authors.lastname: de Sousa
authors.affiliation: Programa de Carcinogênese Molecular; Centro de Pesquisa (CPQ); Instituto Nacional de Câncer (INCA); Rio de Janeiro, Brazil; Departamento de Ginecologia Oncológica; Instituto Nacional de Câncer (INCA); Rio de Janeiro, Brazil.
authors.forename: Claudia Bessa Pereira
authors.initials: CB
authors.lastname: Chaves
authors.affiliation: Departamento de Ginecologia Oncológica; Instituto Nacional de Câncer (INCA); Rio de Janeiro, Brazil.
authors.forename: Janina Ferreira Loureiro
authors.initials: JF
authors.lastname: Huguenin
authors.affiliation: Divisão de Patologia (DIPAT); Instituto Nacional de Câncer (INCA); Rio de Janeiro, Brazil.
authors.forename: Fábio Carvalho de Barros
authors.initials: FC
authors.lastname: Moreira
authors.affiliation: Divisão de Patologia (DIPAT); Instituto Nacional de Câncer (INCA); Rio de Janeiro, Brazil.
authors.forename: Bruno Souza Bianchi
authors.initials: BS
authors.lastname: de Reis
authors.affiliation: Divisão de Patologia (DIPAT); Instituto Nacional de Câncer (INCA); Rio de Janeiro, Brazil.
authors.forename: Leila
authors.initials: L
authors.lastname: Chimelli
authors.affiliation: Epidemiologia Clínica Aplicada à Oncologia; Instituto Nacional de Câncer (INCA); Rio de Janeiro, Brazil.
authors.forename: Anke
authors.initials: A
authors.lastname: Bergmann
authors.affiliation: Programa de Carcinogênese Molecular; Centro de Pesquisa (CPQ); Instituto Nacional de Câncer (INCA); Rio de Janeiro, Brazil; Laboratório de Toxicologia e Biologia Molecular; Departamento de Bioquímica; Instituto de Biologia Roberto Alcantara Gomes (IBRAG); Universidade do Estado do Rio de Janeiro (UERJ); Rio de Janeiro, Brazil.
authors.forename: Tatiana de Almeida
authors.initials: Tde A
authors.lastname: Simão
authors.affiliation: Programa de Carcinogênese Molecular; Centro de Pesquisa (CPQ); Instituto Nacional de Câncer (INCA); Rio de Janeiro, Brazil; Laboratório de Toxicologia e Biologia Molecular; Departamento de Bioquímica; Instituto de Biologia Roberto Alcantara Gomes (IBRAG); Universidade do Estado do Rio de Janeiro (UERJ); Rio de Janeiro, Brazil.
authors.forename: Luis Felipe Ribeiro
authors.initials: LF
authors.lastname: Pinto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018269:Carcinoma, Endometrioid / Q000378:metabolism* / Q000473:pathology; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D018450:Disease Progression; D016889:Endometrial Neoplasms / Q000378:metabolism* / Q000473:pathology; D004717:Endometrium / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D059467:Transcriptome
chemical_list: D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins; C086680:ETV5 protein, human; C493728:RUNX1 protein, human; D014157:Transcription Factors
keywords: ERM/ETV5; RUNX1/AML1; differential gene expression; endometrioid endometrial carcinoma; myometrial invasion
references.citation: Gynecol Oncol. 1983 Feb;15(1):10-7
references.pmid: 6822361
references.citation: J Pathol. 2005 Dec;207(4):422-9
references.pmid: 16175655
references.citation: Oncogene. 2004 May 24;23(24):4198-208
references.pmid: 15156173
references.citation: Cancer Res. 2007 Jul 15;67(14):6753-9
references.pmid: 17638886
references.citation: J Biol Chem. 2004 Apr 9;279(15):15630-8
references.pmid: 14752096
references.citation: Trends Biochem Sci. 1998 Jun;23(6):213-6
references.pmid: 9644975
references.citation: Hum Reprod Update. 2010 Nov-Dec;16(6):631-50
references.pmid: 20543200
references.citation: Int J Cancer. 2009 Jul 15;125(2):257-63
references.pmid: 19384951
references.citation: Clin Obstet Gynecol. 2011 Jun;54(2):215-8
references.pmid: 21508690
references.citation: Eur J Cancer. 2005 Nov;41(16):2462-78
references.pmid: 16213704
references.citation: Nat Rev Clin Oncol. 2011 May;8(5):261-71
references.pmid: 21221135
references.citation: Oncogene. 2004 Nov 11;23(53):8603-10
references.pmid: 15467760
references.citation: Oncogene. 2002 Nov 14;21(52):7981-90
references.pmid: 12439748
references.citation: Eur J Gynaecol Oncol. 1995;16(2):138-46
references.pmid: 7641741
references.citation: Folia Histochem Cytobiol. 2010 Sep 30;48(3):319-22
references.pmid: 21071332
references.citation: FASEB J. 2013 May;27(5):1874-86
references.pmid: 23371066
references.citation: Cancer Control. 2009 Jan;16(1):8-13
references.pmid: 19078924
references.citation: Gynecol Oncol. 2009 Jul;114(1):121-7
references.pmid: 19406460
references.citation: Oncogene. 2012 Nov 8;31(45):4778-88
references.pmid: 22266854
references.citation: Int J Cancer. 2011 Apr 1;128(7):1644-51
references.pmid: 21280035
references.citation: Leuk Res. 2007 Jun;31(6):839-51
references.pmid: 17023045
references.citation: Clin Transl Oncol. 2007 May;9(5):272-7
references.pmid: 17525037
references.citation: J Clin Oncol. 2007 May 20;25(15):2042-8
references.pmid: 17513808
references.citation: APMIS. 2009 Oct;117(10):693-707
references.pmid: 19775337
references.citation: Hum Mol Genet. 2000 Dec 12;9(20):2981-91
references.pmid: 11115842
references.citation: Cancer Res. 2004 Dec 15;64(24):8846-53
references.pmid: 15604243
references.citation: Endocr Relat Cancer. 2010 Oct 29;17(4):1007-19
references.pmid: 20843938
references.citation: EMBO J. 2001 Feb 15;20(4):723-33
references.pmid: 11179217
references.citation: Carcinogenesis. 2009 Aug;30(8):1288-97
references.pmid: 19443906
references.citation: Br J Cancer. 2011 Jun 28;105(1):124-30
references.pmid: 21673681
references.citation: Br J Haematol. 2009 May;145(3):412-23
references.pmid: 19298589
references.citation: J Biol Chem. 1995 Oct 6;270(40):23795-800
references.pmid: 7559555
references.citation: J Obstet Gynaecol Res. 2008 Oct;34(5):776-83
references.pmid: 18958927
references.citation: Hum Mol Genet. 2001 Apr;10(7):735-40
references.pmid: 11257106
references.citation: Clin Cancer Res. 2004 Nov 1;10(21):7297-303
references.pmid: 15534105
references.citation: Biochem Mol Med. 1997 Aug;61(2):127-35
references.pmid: 9259977